Trump Announces Medicaid Drug Pricing Deals with Nine Companies

The Trump administration announced on Monday that it has struck new Medicaid drug‑pricing agreements with nine midsize biotechnology and pharmaceutical companies. In a statement released from the Oval Office, President Trump said the deals would ensure that “every drug will be at the lowest prices available anywhere in the world.” The agreements were signed in the presence of company executives and are intended to reduce the cost of prescription medications for state Medicaid programs.

Under the terms of the agreements, the companies will charge state Medicaid programs the same price that the federal government pays for each drug. The contracts cover a range of specialty medications, many of which are used to treat chronic and rare conditions. The administration claims the deals will provide predictable, low-cost access to essential therapies for millions of Medicaid beneficiaries across the country.

The agreements are part of a broader effort to curb rising prescription drug costs in the United States. While the administration has highlighted the potential savings for Medicaid recipients, critics have urged caution, noting that the long‑term impact on drug innovation and market competition remains unclear. The deals will be monitored by state Medicaid agencies to ensure compliance with the agreed pricing terms.